Epidermal growth factor receptor inhibitors enhance susceptibility to Fas-mediated apoptosis in oral squamous cell carcinoma cells
- 6 August 2007
- journal article
- Published by Elsevier in Oral Oncology
- Vol. 44 (4) , 361-368
- https://doi.org/10.1016/j.oraloncology.2007.04.006
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group StudyJournal of Clinical Oncology, 2005
- Phase II Multicenter Study of the Epidermal Growth Factor Receptor Antibody Cetuximab and Cisplatin for Recurrent and Refractory Squamous Cell Carcinoma of the Head and NeckJournal of Clinical Oncology, 2005
- Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and NeckJournal of Clinical Oncology, 2004
- Molecular mechanisms underlying the interaction between ZD1839 (‘Iressa’) and cisplatin/5-fluorouracilBritish Journal of Cancer, 2003
- Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckJournal of Clinical Oncology, 2003
- Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasiaSeminars in Oncology, 2002
- Monoclonal antibodies to target epidermal growth factor receptor–positive tumorsCancer, 2002
- Head and Neck CancerNew England Journal of Medicine, 2001
- Genetic mechanisms in squamous cell carcinoma of the head and neckOral Oncology, 2001
- Quantitative immunohistochemical analysis of transforming growth factor-α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neckCancer, 1996